Disorder in clotting pattern after antiretroviral treatment with emtricitabine in an HIV-positive haemophiliac patient.
Hepatitis C virus and human immunodeficiency virus (HIV) co-infection is a major problem for haemophiliacs treated before 1985 with non-virally inactivated clotting factor concentrates. Over the past 10 years, the management of HIV infection has been better standardised by optimisation of highly active antiretroviral therapy, which leads to suppression of viral load and increases the number of CD4+ T cells. However, despite HIV infection being effectively controlled, patients experience short- and long-term adverse effects. This report describes a disorder in the clotting pattern with a decrease (approximately 60%) in the efficiency of antihaemophilic factor infusion after antiretroviral treatment with emtricitabine (a reverse transcriptase inhibitor) in an HIV-positive haemophiliac patient.
Liras
Antonio
A
Scientific Commission of the Royal Foundation 'Victoria Eugenia' of Haemophilia, Madrid, Spain. aliras@hotmail.com
D000998:Antiviral Agents / Q000009:adverse effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced*; D003029:Coagulants / Q000627:therapeutic use; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000068679:Emtricitabine; D005169:Factor VIII / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged
D000998:Antiviral Agents; D003029:Coagulants; D003841:Deoxycytidine; D005169:Factor VIII; D000068679:Emtricitabine